OncoMatch/Clinical Trials/NCT05651828
Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma
Is NCT05651828 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies Vismodegib 150 MG Oral Capsule for advanced basal cell carcinoma.
Treatment: Vismodegib 150 MG Oral Capsule — The purpose of this study is to compare how well tolerated and effective four different dosing schedules (two personalized, intermittent dosing schedules as compared to a fixed intermittent and continuous dosing regimen) work in people with advanced basal cell carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: hedgehog inhibitor
Exception: allowed if more than 6 months prior
Received prior hedgehog inhibitor therapy in the last 6 months
Lab requirements
Blood counts
adequate bone marrow function as defined in the protocol
Kidney function
adequate renal function as defined in the protocol
Liver function
adequate hepatic function as defined in the protocol
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Moffitt Cancer Center · Tampa, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify